Adding ribociclib, a targeted drug that disrupts cancer cells, to standard hormone therapy was found to boost survival among premenopausal patients who have an advanced form of the disease. The research, led by Dr Sara Hurvitz of the University of California in Los Angeles, followed pre-menopausal women under the age of 59 who had advanced hormone receptor-positive, HER2-negative breast cancer. The patients were assigned either ribociclib, which targets and interferes with processes in the cells that cause cancer to grow, or a placebo. All the women also received hormone therapy.
Emerging Areas in Chemotherapy, Hormone Therapy and Other Drug Therapies
Advances in Chemotherapy & Hormone Therapy | Susan G. Komen®
In fact,breast cancer is the most common cancer among women, except for non-melanoma skin cancer, and women living in North America have the highest rate of breast cancer in the world. In , about , new cases of invasive breast cancer will be diagnosed among women in the US, and an estimated 1, cases of breast cancer will be diagnosed in men. Breast cancer is the second leading cause of cancer death in women,exceeded only by lung cancer. In , 40, women and men will die from breast cancer.
New breast cancer treatment offers hope of longer life to younger women
There have been several recent medical advances in the prevention and treatment of breast cancer that I'd like to share with you. First, let's look at risk factors and prevention. A patient may be at increased risk for breast cancer based on her personal and family history. Some risk factors are lifestyle related, including obesity, inactivity and the use of alcohol. Other risks you cannot control, such as age, gender, family history and genetics.
Treatment advances across the spectrum of cancers have continued at a rapid pace. Lung cancer experienced significant treatment breakthroughs this year, primarily in immunotherapy, as it has in the past several years. Other immunotherapy trials brought new treatment options to patients with a range of solid tumor and blood cancers.